



March 31, 2026

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Shota Kikuchi
Director, Corporate Planning
Telephone: 03-6374-9702

KYORIN Enters into License Agreement with BIODOL for Novel Neuropathic Pain Treatment

KYORIN Pharmaceutical Co., Ltd. announced today that it has exercised its option under the option agreement signed in January 2025 with BIODOL Therapeutics (Montarnaud France, CEO: Fabien Granier) and entered into a license agreement for BDT272, a novel pain treatment candidate discovered by BIODOL.

Under the terms of this agreement, KYORIN has obtained exclusive rights to develop, manufacture, and commercialize BDT272 in Japan, South Korea, and Taiwan. In consideration for these rights, KYORIN will make payments to BIODOL up to 79 million euros based on upfront payment, milestone payments related to the progress of development, regulatory approval and the achievement of certain net sales targets. In addition, KYORIN will pay royalties to BIODOL based on net sales.

BDT272, completing Ph1 studies, is anticipated to demonstrate effective analgesic properties through the inhibition of FLT3, a receptor tyrosine kinase implicated in the pathogenesis and maintenance of pain condition such as neuropathic pain.

KYORIN aims to create high-value new drugs that meet medical needs and focuses on pain as one of our key strategic therapeutic area for research and development. KYORIN anticipates that this innovative pain treatment candidate will provide a new treatment option for patients suffering from pain conditions.

The impact on the consolidated earnings forecast for the fiscal year ending March 2026 is expected to include the upfront payment to BIODOL under this agreement, which will be recorded as SG&A expenses (R&D expenses) for the current fiscal year. Any matters requiring timely disclosure arise, KYORIN will make prompt announcements accordingly.

[Reference]

About BIODOL Therapeutics

BIODOL Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key driver in initiating and sustaining neuropathic pain (Nature Communications, 2018). Its groundbreaking research has also demonstrated that inhibiting FLT3 signaling eliminates opioid tolerance and hyperalgesia while preserving analgesic efficacy (Nature Communications, 2024). BIODOL Therapeutics is focused on developing allosteric inhibitors of the FLT3 receptor to address various types of pain. The company holds exclusive rights to a portfolio of four patents and has received support from BPI France, SATT AxLR, Inserm Transfert, Région Occitanie, the French National Research Agency, SEMIA Incubator, and the Montpellier Business and Innovation Centre. BIODOL Therapeutics was assisted by MCE Carrel law firm for this transaction.